Prevalence of pre-existing cognitive impairment in patients treated for cancer and the impact of cancer treatment on cognitive outcomes: A scoping review

  • 0Lawrence Bloomberg Faculty of Nursing, University of Toronto, Toronto, Canada.

|

|

Summary

This summary is machine-generated.

Pre-existing cognitive impairment (CI) is common in cancer patients, with prevalence varying widely based on screening methods. Further research is needed on the impact of cancer treatment on these patients.

Area Of Science

  • Geriatric Oncology
  • Neuro-oncology
  • Cognitive Science

Background

  • Pre-existing cognitive impairment (CI) is underreported in cancer patients, impacting treatment outcomes.
  • Older adults with CI may face higher risks of treatment failure, morbidity, and mortality.
  • Limited data exists on the prevalence and impact of CI in cancer populations.

Purpose Of The Study

  • To determine the prevalence of pre-existing CI in cancer patients.
  • To assess the impact of cancer treatment on cognitive outcomes in patients with pre-existing CI.

Main Methods

  • Scoping review following Arksey and O'Malley framework.
  • Searched MEDLINE, EMBASE, CINAHL for studies on CI in cancer patients aged 60+.
  • Included studies reporting CI prevalence before cancer treatment.

Main Results

  • 23 manuscripts (21 studies) met inclusion criteria.
  • Prevalence of CI: 6% (administrative data) vs. 26% (cognitive screening tools).
  • One study reported postoperative delirium in 27.9% of CI patients; other treatment impacts were not studied.

Conclusions

  • Pre-existing CI is prevalent but highly variable in cancer patients.
  • Variability linked to differing study criteria and sample sizes.
  • More research is needed on treatment effects on cognition in this population.

Related Concept Videos